Grischa Hoffmann1, Georg Lutter, Jochen Cremer. 1. Klinik für Herz- und Gefässchirurgie, Universitätsklinikum Schleswig-Holstein, Campus Kiel, Arnold-Heller-Strasse 7, Kiel, Germany. grischa.hoffmann@gmx.de
Abstract
INTRODUCTION: The choice of type of heart valve prosthesis is determined by the patient's age since bioprostheses have a limited lifespan. This article reviews current recommendations and the literature on cardiac valve replacement. METHODS: Selective literature search in Medline/PubMed back to 1996 and review of current national and international recommendations from specialist societies. RESULTS: The recommendations guiding the type of heart valve replacement have been revised in recent years. Of particular interest are the new generation of biological prostheses with extended durability, a growing use of stentless bioprostheses, a decrease in mortality of reoperation and an increase in life expectancy. Comorbidities such as chronic renal insufficiency or chronic atrial fibrillation are no longer contraindications to bioprosthesis. The number of heart valve replacements in recent years rose despite a concomitant increase in valve repairs. Aortic valves are being increasingly replaced by bioprostheses. DISCUSSION: The choice of heart valve prosthesis should be tailored to each patient taking into account the patient's age, life expectancy, comorbidities, and life style. Different decisions may be made now than those based on earlier recommendations resulting in an individualized treatment, in patients over the age of 65 or 70.
INTRODUCTION: The choice of type of heart valve prosthesis is determined by the patient's age since bioprostheses have a limited lifespan. This article reviews current recommendations and the literature on cardiac valve replacement. METHODS: Selective literature search in Medline/PubMed back to 1996 and review of current national and international recommendations from specialist societies. RESULTS: The recommendations guiding the type of heart valve replacement have been revised in recent years. Of particular interest are the new generation of biological prostheses with extended durability, a growing use of stentless bioprostheses, a decrease in mortality of reoperation and an increase in life expectancy. Comorbidities such as chronic renal insufficiency or chronic atrial fibrillation are no longer contraindications to bioprosthesis. The number of heart valve replacements in recent years rose despite a concomitant increase in valve repairs. Aortic valves are being increasingly replaced by bioprostheses. DISCUSSION: The choice of heart valve prosthesis should be tailored to each patient taking into account the patient's age, life expectancy, comorbidities, and life style. Different decisions may be made now than those based on earlier recommendations resulting in an individualized treatment, in patients over the age of 65 or 70.
Authors: Kim Rajappan; Giovanni Melina; Nicholas G Bellenger; Mohamed Amrani; Asghar Khaghani; Dudley J Pennell; Magdi H Yacoub Journal: J Heart Valve Dis Date: 2002-01
Authors: Gideon Cohen; George T Christakis; Campbell D Joyner; Christopher D Morgan; Miguel Tamariz; Naoji Hanayama; Hari Mallidi; J P Szalai; Marko Katic; Vivek Rao; Stephen E Fremes; Bernard S Goldman Journal: Ann Thorac Surg Date: 2002-03 Impact factor: 4.330
Authors: K Hammermeister; G K Sethi; W G Henderson; F L Grover; C Oprian; S H Rahimtoola Journal: J Am Coll Cardiol Date: 2000-10 Impact factor: 24.094
Authors: P Stassano; L Di Tommaso; D F Vitale; M Monaco; G Iannelli; M Mottola; A Musumeci; N Spampinato Journal: Thorac Cardiovasc Surg Date: 2006-12 Impact factor: 1.827
Authors: Alberto Takeshi Kiyose; Erica Aranha Suzumura; Lígia Laranjeira; Anna Maria Buehler; José Amalth Espírito Santo; Otavio Berwanger; Antonio Carlos de Camargo Carvalho; Angelo Amato de Paola; Valdir Ambrósio Moises; Alexandre Biasi Cavalcanti Journal: Arq Bras Cardiol Date: 2019-01-07 Impact factor: 2.000